The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials

Gillian Mead, Maree L Hackett, Erik Lundström, Veronica Murray, Graeme J Hankey, Martin Dennis, Gillian Mead, Maree L Hackett, Erik Lundström, Veronica Murray, Graeme J Hankey, Martin Dennis

Abstract

Background: Several small trials have suggested that fluoxetine improves neurological recovery from stroke. FOCUS, AFFINITY and EFFECTS are a family of investigator-led, multicentre, parallel group, randomised, placebo-controlled trials that aim to determine whether routine administration of fluoxetine (20 mg daily) for 6 months after acute stroke improves patients' functional outcome.

Methods/design: The three trial investigator teams have collaboratively developed a core protocol. Minor variations have been tailored to the national setting in the UK (FOCUS), Australia and New Zealand (AFFINITY) and Sweden (EFFECTS). Each trial is run and funded independently and will report its own results. A prospectively planned individual patient data meta-analysis of all three trials will subsequently provide the most precise estimate of the overall effect of fluoxetine after stroke and establish whether any effects differ between trials and subgroups of patients. The trials include patients ≥18 years old with a clinical diagnosis of stroke, persisting focal neurological deficits at randomisation between 2 and 15 days after stroke onset. Patients are randomised centrally via web-based randomisation systems using a common minimisation algorithm. Patients are allocated fluoxetine 20 mg once daily or matching placebo capsules for 6 months. Our primary outcome measure is the modified Rankin scale (mRS) at 6 months. Secondary outcomes include the Stroke Impact Scale, EuroQol (EQ5D-5 L), the vitality subscale of the Short-Form 36, diagnosis of depression, adherence to medication, adverse events and resource use. Outcomes are collected at 6 and 12 months. The methods of collecting these data are tailored to the national setting. If FOCUS, AFFINITY and EFFECTS combined enrol 6000 participants as planned, they would have 90 % power (alpha 5 %) to detect a common odds ratio of 1.16, equivalent to a 3.7 % absolute difference in percentage with mRS 0-2 (44.0 % to 47.7 %). This is based on an ordinal analysis of mRS adjusted for baseline variables included in the minimisation algorithm.

Discussion: If fluoxetine is safe and effective in promoting functional recovery, it could be rapidly, widely and affordably implemented in routine clinical practice and reduce the burden of disability due to stroke.

Focus: ISRCTN83290762 (23/05/2012), AFFINITY: ACTRN12611000774921 (22/07/2011).

Effects: ISRCTN13020412 (19/12/2014).

Figures

Fig. 1
Fig. 1
Patient flow in the FOOD, AFFINITY and EFFECTS trials

References

    1. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol. 2007;6:182–7. doi: 10.1016/S1474-4422(07)70031-5.
    1. Shin TK, Kang MS, Lee HY, Seo MS, Kim SG, Kim CD, et al. Fluoxetine and sertraline attenuate postischemic brain injury in mice. Korean J Physiol Pharmacol. 2009;13(3):257–63. doi: 10.4196/kjpp.2009.13.3.257.
    1. Lim C-M, Kim S-W, Park J-Y, Kim C, Yoon SH, Lee J-K. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res. 2009;87(4):1037–45. doi: 10.1002/jnr.21899.
    1. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol. 2007;18(5–6):391–418. doi: 10.1097/FBP.0b013e3282ee2aa8.
    1. Wang J-W, David DJ, Monckton JE, Battaglia F, Hen R. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci. 2008;28(6):1374–84. doi: 10.1523/JNEUROSCI.3632-07.2008.
    1. Russo-Neustadt AA, Beard RC, Huang YM, Cotman CW. Physical activity and antidepressant treatment potentiate the expression of specific brain-derived neurotrophic factor transcripts in the rat hippocampus. Neuroscience. 2000;101(2):305–12. doi: 10.1016/S0306-4522(00)00349-3.
    1. Coppell AL, Pei Q, Zetterstrom TSC. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology. 2003;44(7):903–10. doi: 10.1016/S0028-3908(03)00077-7.
    1. Mikami K, Jorge RE, Adams HP, Jr, Davis PH, Leira EC, Jang M, et al. Effect of antidepressants on the course of disability following stroke. Am J Geriatr Psychiatr. 2011;19(12):1007–15. doi: 10.1097/JGP.0b013e31821181b0.
    1. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci. 1996;16(7):2365–72.
    1. Nikisch G, Mathe AA, Czernik A, Thiele J, Bohner J, Eap CB, et al. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology (Berl) 2005;181(4):751–60. doi: 10.1007/s00213-005-0034-3.
    1. Barugh AJ, Gray P, Shenkin SD, MacLullich AMJ, Mead GE. Cortisol levels and the severity an outcome of acute stroke. A systematic review. J Neurol. 2014; in press.
    1. McCann SK, Irvine C, Mead GE, Sena ES, Currie GL, Egan KE, et al. Efficacy of antidepressants in animal models of ischemic stroke: a systematic review and meta-analysis. Stroke. 2014;45:3055–63. doi: 10.1161/STROKEAHA.114.006304.
    1. Loubinoux I, Boulanouar K, Ranjeva JP, Carel C, Berry I, Rascol O, et al. Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. J Cereb Blood Flow Metab. 1999;19(12):1365–75. doi: 10.1097/00004647-199912000-00010.
    1. Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol. 2001;50(6):718–29. doi: 10.1002/ana.1257.
    1. Acler M, Robol E, Fiaschi A, Manganotti P. A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. J Neurol. 2009;256(7):1152–8. doi: 10.1007/s00415-009-5093-7.
    1. Chollet F, Tardy J, Albucher J-F, Thalamas C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011; doi:10.1016/S1474-4422(10)70314-8
    1. Mead GE, Hankey GJ, Kutlubaev MA, Lee R, Bailey M, Hackett ML. Selective serotonin reuptake inhibitors (SSRIs) for stroke. Cochrane Database Syst Rev. 2011, Issue 11. Art. No.: CD009286. DOI: 10.1002/14651858.CD009286
    1. National Institute for Health and Clinical Excellence. (NICE 2009) Depression in adults with a chronic physical health problem treatment and management. NICE, London 2009 ISBN 978-1-84936-101-9
    1. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort. BMJ. 2011;343:d4551. doi: 10.1136/bmj.d4551.
    1. Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ. 2011;183:1835–43. doi: 10.1503/cmaj.100912.
    1. Schelleman H, Brensinger CM, Bilker WB, Hennessy S. Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk: a case–control study. PLoS One. 2011;6 doi: 10.1371/journal.pone.0021447.
    1. Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology. 2012;79:1862–5. doi: 10.1212/WNL.0b013e318271f848.
    1. Mortensen JK, Larsson H, Johnsen SP, Andersen G. Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke: a nationwide propensity score-matched follow-up study. Stroke. 2013;44:420–6. doi: 10.1161/STROKEAHA.112.674242.
    1. Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry. 2007;62:345–54. doi: 10.1016/j.biopsych.2006.09.023.
    1. Kutlabaev MA, Hackett ML. Part II: Predictors of depression after stroke and impact of depression on stroke outcome: an updated systematic review of observational studies. Int J Stroke. 2014;9:1026–36. doi: 10.1111/ijs.12356.
    1. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604–7. doi: 10.1161/01.STR.19.5.604.
    1. Counsell C, Dennis M, McDowall M, Warlow C. Predicting outcome after acute stroke: development and validation of new models. Stroke. 2002;33:1041–7. doi: 10.1161/hs0402.105909.
    1. Brott TG, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864–70. doi: 10.1161/01.STR.20.7.864.
    1. Altman DG, Bland JM. Treatment allocation by minimisation. BMJ. 2005;330:843. doi: 10.1136/bmj.330.7495.843.
    1. White R, Bradnam V. Handbook of drug administration via enteral feeding tubes (2nd Ed) Pharmaceutical press, London 2010 ISBN 978 0 85369 928 6.
    1. Bruno A, Shah N, Lin C, Close B, Hess D, Davis K, et al. Improving modified Rankin scale assessment with a simplified questionnaire. Stroke. 2010;41:1048–50. doi: 10.1161/STROKEAHA.109.571562.
    1. Bruno A, Akinwuntan AE, Lin C, Close B, Davis K, Baute V, et al. Simplified Modified Rankin Scale Questionnaire: reproducibility over the telephone and validation With quality of life. STROKEAHA.111.613273 Published online before print June 16, 2011, doi: 10.1161/
    1. Dennis M, Mead G, Doubal F, Graham C. Determining the modified Rankin score after stroke by postal and telephone questionnaires. Stroke. 2012;43(3):851–3. doi: 10.1161/STROKEAHA.111.639708.
    1. Duncan PW, Wallace D, Lai SM, Johnson D, Embretson S, Laster LJ. The Stroke Impact Scale Version 2.0: evaluation of reliability, validity and sensitivity to change. Stroke. 1999;30:2131–40. doi: 10.1161/01.STR.30.10.2131.
    1. Duncan P, Reker D, Kwon S, Lai SM, Studenski S, Perera S, et al. Measuring stroke impact with the stroke impact scale: telephone versus mail administration in veterans with stroke. Med Care. 2005;43:507–15. doi: 10.1097/.
    1. Kwon S, Duncan P, Studenski S, Perera S, Lai SM, Reker D. Measuring stroke impact with SIS: construct validity of SIS telephone administration. Qual Life Res. 2006;15:367–76. doi: 10.1007/s11136-005-2292-2.
    1. Berwick DM, Murphy JM, Goldman PA, Ware JEJR, Barsky AJ, Weinstein MC. Performance of a five-item mental health screening test. Med Care. 1991;29:169–76. doi: 10.1097/00005650-199102000-00008.
    1. McCabe CJ, Thomas KJ, Brazier JE, Coleman P. Measuring the mental health status of a population: a comparison of the GHQ-12 and the SF-36 (MHI-5) Br J Psychiatry. 1996;169:516–21. doi: 10.1192/bjp.169.4.516.
    1. Hoeymans N, Garssen AA, Westert GP, Verhaak PFM. Measuring mental health of the Dutch population: a comparison of the GHQ-12 and the MHI-5. Health Qual Life Outcomes. 2004, 2:23.
    1. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9. doi: 10.1192/bjp.134.4.382.
    1. Williams JBW, Kobak KA. Development and reliability of a structured interview guide for the Montgomery-Asberg Depression Rating Scale (SIGMA)". Br J Psychiatry. 2008;192:52–8. doi: 10.1192/bjp.bp.106.032532.
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington DC: American Psychiatric Association; 199
    1. Williams LS, Brizendine EJ, Plue L, Bakas T, Tu W, Hendrie H, et al. Performance of the PHQ-9 as a screening tool for depression after stroke. Stroke. 2005;36:635–8. doi: 10.1161/01.STR.0000155688.18207.33.
    1. Mead GE, Lynch J, Greig CA, Young A, Lewis SJ, Sharpe M. Evaluation of fatigue scales in stroke. Stroke. 2007;38:2090–5. doi: 10.1161/STROKEAHA.106.478941.
    1. Mead GE, Graham C, Dorman P, Bruins-Slot K, Lewis SC, Dennis MPAG, et al. Fatigue after stroke: baseline predictors and influence on survival. Analysis of data from UK patients recruited in the International Stroke Trial. PLoS One. 2011;6(3) doi: 10.1371/journal.pone.0016988.
    1. de Jager CA, Budge MM, Clarke R. Utility of TICS-M for the assessment of cognitive function in older adults. Int J Geriatr Psychiatry. 2003;18:318–24. doi: 10.1002/gps.830.
    1. Aggarwal A, Kean E. Comparison of the Folstein Mini Mental State Examination (MMSE) to the Montreal Cognitive Assessment (MoCA) as a cognitive screening tool in an inpatient rehabilitation setting. Neurosci Med. 2010;1:39–42. doi: 10.4236/nm.2010.12006.
    1. Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011;20:1727–36. doi: 10.1007/s11136-011-9903-x.
    1. The Optimising Analysis of Stroke Trials (OAST) Collaboration Can we improve the statistical analysis of stroke trials? Statistical Reanalysis of Functional Outcomes in Stroke Trials. Stroke. 2007;38:1911–5. doi: 10.1161/STROKEAHA.106.474080.
    1. Bruins Slot K, Berge E, Dorman P, Lewis S, Dennis M, Sandercock P. Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ. 2008;336:376–9. doi: 10.1136/.
    1. The FOOD Trial Collaboration Routine oral nutritional supplementation for stroke patients in hospital (FOOD): a multicentre randomised controlled trial. Lancet. 2005;365:755–63. doi: 10.1016/S0140-6736(05)70998-3.
    1. The FOOD Trial Collaboration Effect of timing and method of enteral tube feeding for dysphagic stroke patients (FOOD): a multicentre randomised controlled trial. Lancet. 2005;365:764–72. doi: 10.1016/S0140-6736(05)70999-5.
    1. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial. Lancet. 2012;379(9834):2352–63. doi: 10.1016/S0140-6736(12)60768-5.
    1. The CLOTS. Collaboration T, Dennis M, Sandercock P, Reid J, Graham C, et al. The effect of graduated compression stockings on long-term outcomes after stroke: The CLOTS Trials 1 and 2. Stroke. 2013;44:1075–9. doi: 10.1161/STROKEAHA.111.680298.
    1. CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration. Effect of intermittent pneumatic compression on disability, living circumstances, quality of life and hospital costs after stroke: a randomised trial. Lancet Neurol. 2014;13:1186–92.
    1. Kroenke K1, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care 2003;41:1284–92
    1. Bamford J, Sandercock P, Dennis MS, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521–6. doi: 10.1016/0140-6736(91)93206-O.
    1. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35–41. doi: 10.1161/01.STR.24.1.35.
    1. Ware JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–33. doi: 10.1097/00005650-199603000-00003.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel